Clinical Trial Update: Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study [Phase 3]

View source ↗

Summary

This Phase 3 trial update describes the ERADICATE study, which investigates adding darolutamide to androgen deprivation therapy after surgery in men with high-r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Prostate Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING